Since the advent of COVID-19 mRNA vaccines, the space has steadily grown hotter, a situation on which Anima Biotech Inc. has capitalized by way of a potential $580 million-plus deal with Abbvie Inc. to deploy mRNA biology modulators for three targets across oncology and Immunology. Read More

Nextpoint Therapeutics Inc. closed an $80 million series B round to move two novel immune checkpoint inhibitor programs into clinical development in the coming year. The Cambridge, Mass.-based firm is planting a flag in an area of immune signaling that has been largely overlooked by drug developers until now. Read More

After long years of painstaking work, the commercialization of cell and gene therapies picked up pace in 2022, with multiple approvals. More progress is expected in 2023, with several firsts in the offing and products for larger patient populations reaching the market. Read More

The $60.8 billion collected by biopharma companies throughout 2022 is a sharp drop from each of the two prior years, down by 48.6% from 2021 and 54.8% from 2020. Each were standout years by any measure and a direct result of the investment fervor for the industry brought on by the COVID-19 pandemic. That exuberance diminished in the last year as investors tightened their grips due to economic uncertainties. Read More

Clinical trials in China are growing up in much the same way the R&D enterprise in China has grown up. They are evolving and becoming more sophisticated, reflecting the maturation of the R&D environment around them. Read More

Citing federal preemption, the U.S. Court of Appeals for the First Circuit tossed multidistrict litigation (MDL) involving GSK plc’s labeling of Zofran, an antiemetic approved for postoperative use and in conjunction with chemo or radiation, but that is commonly used off-label in pregnancy. Read More

New hires and promotions in the biopharma industry, including: Acadia, Aivita, Akero, Amarin, Aptamer, Dinaqor, Gameto, Medison, Regenxbio, Storm, TFF, Veru, Vivus. Read More

Biopharmas raising money in public or private financings, including: Aeon, Helsinn, Jaguar, Magdalena, Linkinvax, Palisade, Recode. Read More

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Achieve, Adagene, Alentis, Allovir, Alucent, Anebulo, Arrowhead, Avenge, Biocryst, Biomarin, Cerevance, Cyclo, Day One, Gaba, IGM, IO, Jacobio, Legacy, Maggie's Pearl, Morphosys, Myrtelle, Neuroderm, Ocuphire, Poolbeg, Shanton, Small, Sorrento, Spexis, Theriva, Trevena, Viking, Viracta, Viridian. Read More

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Ajinomoto, Atavistik, Avanzanite, Boehringer Ingelheim, Biontech, Cerveau, Defence, Epivax, Exelixis, Foundation Medicine, Giiant, Instadeep, Janone, Jasper, Karyopharm, Medtherapy, Newcourt, Othair, Plex, Probiogen, Prothena, Psyence, Santhera, Sifi, Soin, Teva, Zoetis. Read More

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Biogen, Biora, Cantex, Eisai, Hifibio, Ideaya, Immorna, Krystal, Neurelis, Otsuka, Phio, Revance, Santhera, Secura, SK, Tenaya. Read More